Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department

Last updated: February 27, 2024
Sponsor: University of Monastir
Overall Status: Active - Recruiting

Phase

3

Condition

Pain (Pediatric)

Pain

Chronic Pain

Treatment

Magnesium sulfate

Clinical Study ID

NCT05325580
Emergency Monastir
  • Ages 18-85
  • All Genders

Study Summary

Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • informed consent
  • age >18 years
  • Acute non-traumatic acute headaches
  • patients treated in ED
  • Magnesium sulfate and aspirin administered intravenously (IV)

Exclusion

Exclusion Criteria:

  • Current regular use of analgesics, anticonvulsants or antidepressants
  • Renal disorder with a low glomerular filtration rate (<60 ml/min)
  • Neuromuscular disorder
  • Pregnant woman
  • Contrindication
  • Allergy to NSAID
  • Traumatic Headache
  • Chronic headache ( headache occurring at least 15 days per month for at least 3months)
  • Hemodynamic instability

Study Design

Total Participants: 424
Treatment Group(s): 1
Primary Treatment: Magnesium sulfate
Phase: 3
Study Start date:
December 01, 2021
Estimated Completion Date:
December 30, 2026

Study Description

Rate of Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department

Connect with a study center

  • University of Monasrtir

    Monastir, 5060
    Tunisia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.